Ranibizumab Biosimilar (Razumab) vs Innovator Ranibizumab (Lucentis) in neovascular age-related macular degeneration (n-AMD)- efficacy and safety (BIRA study)

Articolo

Data di Pubblicazione:

2022

Citazione:

Ranibizumab Biosimilar (Razumab) vs Innovator Ranibizumab (Lucentis) in neovascular age-related macular degeneration (n-AMD)- efficacy and safety (BIRA study) / Sharma, A., Kumar, N., Parachuri, N., Bandello, F., Kuppermann, B.D., Loewenstein, A.. - In: EYE. - ISSN 1476-5454. - 36:5(2022), pp. 1106-1107. [10.1038/s41433-021-01616-9]

Tipologia CRIS:

1.1 Articolo in rivista

Elenco autori: